Amicus Therapeutics Inc. (NASDAQ:FOLD) shares traded 3.39% higher at $11.90 on Wall Street last session.
In accordance with the data, 13 analysts cover Amicus Therapeutics Inc. (NASDAQ:FOLD). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $20.00 and a low of $12.00, we find $16.00. Given the previous closing price of $11.51, this indicates a potential upside of 39.01 percent. FOLD stock price is now 4.08% away from the 50-day moving average and 2.15% away from the 200-day moving average. The market capitalization of the company currently stands at $3.28B.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
It has been rated a hold by 5 analysts and a buy by 8. Brokers who have rated the stock have averaged $15.82 as their price target over the next twelve months.
.
In other news, Crowley John F, Executive Chairman sold 6,044 shares of the company’s stock on May 15. The stock was sold for $67,577 at an average price of $11.18. Upon completion of the transaction, the Executive Chairman now directly owns 962,361 shares in the company, valued at $11.45 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 01, President & CEO Campbell Bradley L sold 11,700 shares of the business’s stock. A total of $138,093 was realized by selling the stock at an average price of $11.80. This leaves the insider owning 823,454 shares of the company worth $9.8 million. Insiders disposed of 1,170,499 shares of company stock worth roughly $13.93 million over the past 1 year. A total of 0.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in FOLD stock. A new stake in Amicus Therapeutics Inc. shares was purchased by POINT72 ASSET MANAGEMENT, L.P. during the first quarter worth $26,765,000. GREAT LAKES ADVISORS, LLC invested $6,828,000 in shares of FOLD during the first quarter. In the first quarter, GHOST TREE CAPITAL, LLC acquired a new stake in Amicus Therapeutics Inc. valued at approximately $5,653,000. RENAISSANCE TECHNOLOGIES LLC acquired a new stake in FOLD for approximately $4,629,000. GREAT POINT PARTNERS I LP purchased a new stake in FOLD valued at around $4,522,000 in the second quarter. In total, there are 320 active investors with 105.77% ownership of the company’s stock.
During the past 12 months, Amicus Therapeutics Inc. has had a low of $7.22 and a high of $13.84. As of last week, the company has a debt-to-equity ratio of 3.83, a current ratio of 2.90, and a quick ratio of 2.70. The fifty day moving average price for FOLD is $11.44 and a two-hundred day moving average price translates $11.66 for the stock.
The latest earnings results from Amicus Therapeutics Inc. (NASDAQ: FOLD) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.18, missing analysts’ expectations of -$0.15 by -0.03. This compares to -$0.30 EPS in the same period last year. The net profit margin was -60.60% and return on equity was -153.70% for FOLD. The company reported revenue of $86.27 million for the quarter, compared to $78.72 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 9.6 percent. For the current quarter, analysts expect FOLD to generate $89.74M in revenue.
Amicus Therapeutics Inc.(FOLD) Company Profile
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children’s Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
